At the ESMO Congress 2024, Andrea Necchi, MD, of San Raffaele Hospital and Scientific Institute, and Karine Tawagi, MD, of University of Illinois, highlight some the challenges that currently exist in the treatment of penile cancer, including “suboptimal” therapy options in the neoadjuvant and adjuvant space and a need for better biomarkers. Dr. Necchi also opines on the trials that have him excited about the future of treatment in this rare disease, such as HERCULES. ...
Testicular, Penile, and Rare Malignancies
Advertisement
Latest News
Paclitaxel, ifosfamide, and cisplatin is a combination commonly used for the treatment of germ cell tumors.
A recent dose-escalation study has demonstrated the safety and efficacy of cabo/nivo or cabo/nivo/ipi for several GU cancers.
Dr. Apolo shares the trials in progress she presented at this year's meeting, including SMART, LASER, and E-VIRTUE.
A recent trial provides the first evidence of efficacy from ICIs in PSCC with a manageable safety profile.
The SWENOTECA cancer care program sought to evaluate survival, toxicity in patients treated with HDCT from 2011 through 2021.
A study to determine the potential utility of ADCs targeting TROP-2 in both localized PSCC and distant metastases.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
Advertisement
Advertisement
Latest News
Dr. Brian Shuch gives a preview of Urology on the Beach 2025, including his session on molecular imaging agents.
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.